Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Boyer

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Health Management Technology|December 2, 2009
Too big to be sharedDavid Boyer
JAMA Ophthalmology|May 3, 2019
Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular DegenerationTimothy L Jackson, David Boyer, Philip J Rosenfeld
Transactions of the American Ophthalmological Society|May 2, 2007
Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) resultsJose S Pulido, Jeffrey L Winters, David Boyer
The American Journal of Medicine|October 12, 2010
Retinal artery embolization from a calcified bicuspid aortic valve causing amaurosis fugaxPoulina Q Uddin, David Boyer, Robert J Siegel
Science (New York, N.Y.)|August 17, 2002
Photothermal imaging of nanometer-sized metal particles among scatterersDavid Boyer, Philippe Tamarat, Abdelhamid Maali, et al.
American Journal of Ophthalmology|June 23, 2020
Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular DegenerationGary C Brown, Melissa M Brown, Sara Rapuano, et al.
Ophthalmic Research|June 21, 2021
The Use of Neuroprotective Agents in Treating Geographic AtrophyHendrik P N Scholl, David Boyer, Andrea Giani, et al.
American Journal of Ophthalmology|July 19, 2020
A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United StatesGary C Brown, Melissa M Brown, Sara B Rapuano, et al.
Clinical Ophthalmology (Auckland, N.Z.)|July 1, 2015
Long-term (60-month) results for the implantable miniature telescope: efficacy and safety outcomes stratified by age in patients with end-stage age-related macular degenerationDavid Boyer, K Bailey Freund, Carl Regillo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 7, 2009
Utility of MetaSite in improving metabolic stability of the neutral indomethacin amide derivative and selective cyclooxygenase-2 inhibitor 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethyl-acetamideDavid Boyer, Jonathan N Bauman, Daniel P Walker, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Health Management Technology|December 2, 2009
Too big to be sharedDavid Boyer
JAMA Ophthalmology|May 3, 2019
Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular DegenerationTimothy L Jackson, David Boyer, Philip J Rosenfeld
Transactions of the American Ophthalmological Society|May 2, 2007
Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) resultsJose S Pulido, Jeffrey L Winters, David Boyer
The American Journal of Medicine|October 12, 2010
Retinal artery embolization from a calcified bicuspid aortic valve causing amaurosis fugaxPoulina Q Uddin, David Boyer, Robert J Siegel
Science (New York, N.Y.)|August 17, 2002
Photothermal imaging of nanometer-sized metal particles among scatterersDavid Boyer, Philippe Tamarat, Abdelhamid Maali, et al.
American Journal of Ophthalmology|June 23, 2020
Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular DegenerationGary C Brown, Melissa M Brown, Sara Rapuano, et al.
Ophthalmic Research|June 21, 2021
The Use of Neuroprotective Agents in Treating Geographic AtrophyHendrik P N Scholl, David Boyer, Andrea Giani, et al.
American Journal of Ophthalmology|July 19, 2020
A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United StatesGary C Brown, Melissa M Brown, Sara B Rapuano, et al.
Clinical Ophthalmology (Auckland, N.Z.)|July 1, 2015
Long-term (60-month) results for the implantable miniature telescope: efficacy and safety outcomes stratified by age in patients with end-stage age-related macular degenerationDavid Boyer, K Bailey Freund, Carl Regillo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 7, 2009
Utility of MetaSite in improving metabolic stability of the neutral indomethacin amide derivative and selective cyclooxygenase-2 inhibitor 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethyl-acetamideDavid Boyer, Jonathan N Bauman, Daniel P Walker, et al.
Pageof 8